A translational story of an idea maturing to a stage III clinical trial

A translational story of an idea maturing to a stage III clinical trial



A translational story of an idea maturing to a stage III clinical trial

pharmaseed logo and mouse

Since 2003, Pharmaseed team members help and advise Biotech and Pharmaceutical companies to  test new technologies in the field of CNS, Vascular, Infectious, Metabolic or Inflammation. Focusing on translational work and new capabilities, Pharmaseed was responsible for the maturation of an innovative idea from the early discovery stage to a Phase III clinical trial tested technology.

 In 2009, Dr. Itschak Lamendorf, Pharmaseed president and founder, and Dr. Yoram Sela, Pharmaseed head of pharmaceutical scientifc board, co-jointly invented and developed a suitable pharmaceutical carrier and a fixed dose combination of two active agents, a dopamine agonist pramipexole and a monoamine oxidase inhibitor rasagiline, indicated for the treatment of Parkinson’s disease.

The combination of the two agents was tested and optimized on different in vitro, as well as in vivo  Parkinson’s Disease pre-clinical model, within Pharmaseed facilities. Pharmaseed’s preclinical testing of the compound provided a solid justification and rationale for further development of a product, which adresses pharmacological as well as pharmaceutical needs.

The technology (P2B001) that was owned by the Israeli company Pharma 2B was further developed clinically reaching the advanced stage of a phase III clinical trial.. In 2015, the company announced that  “A Phase IIb, Twelve Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects with Early Parkinson’s Disease”, successfully met its endpoint and in 2017, Pharma 2B raised $30 millions to test P2B001 in a clinical phase 3.

Pharma Two B raises $30M for Parkinson’s phase 3 from Biogen-backed fund, adds ex-Pfizer CEO to board

Pharma Two B has raised $30 million (€28 million) to complete a phase 3 trial of its Parkinson’s asset P2B001. The round provides a hint of the impact of the recently founded Israel Biotech Fund, which led the investment and is adding ex-Pfizer CEO Jeff Kindler to Pharma Two B’s board.

 

 

 

 

Parkinson’s Disease_brochure#1

For more information on how we can help you
move your drug or device along the development pathway.
Contact Us